The purposes of this study are to determine: 1) The safety
of ALIMTA plus Gemcitabine and any side effects that might be
associated with the combination of these two drugs. 2) Whether
ALIMTA plus Gemcitabine can help patients with mesothelioma
live longer. 3) Whether ALIMTA plus Gemcitabine can make the
tumor smaller or disappear, and for how long. 4) To see if
patients feel better while taking ALIMTA plus Gemcitabine.

Condition

Treatment or
Intervention

Mesothelioma

Drug: ALIMTA Plus
Gemcitabine

This is a Phase II test

In Phase II clinical trials, the study drug or treatment
is given to a larger group of people (100-300) to see if it
is effective and to further evaluate its safety.

Study Type: InterventionalStudy
Design: Treatment

Ages Eligible for Study: 18 Years and
above, Genders Eligible for Study: Both

Criteria

Inclusion Criteria:

Diagnosis of mesothelioma that can be treated with
chemotherapy

Have received no prior chemotherapy for mesothelioma

Have at least one measurable lesion

Have an adequate performance status

Sign an informed consent

Exclusion Criteria:

Previous treatment with chemotherapy for mesothelioma

Treatment with an investigational drug within the last
30 days, previously completed or withdrawn from this study
or any other study investigating ALIMTA